Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Nutriband Inc. Warrant (NTRBW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: NTRBW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.27% | Avg. Invested days 51 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.2 | 52 Weeks Range 0.75 - 5.25 | Updated Date 06/10/2025 |
52 Weeks Range 0.75 - 5.25 | Updated Date 06/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -211.78% |
Management Effectiveness
Return on Assets (TTM) -36.45% | Return on Equity (TTM) -108.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4420276 |
Shares Outstanding - | Shares Floating 4420276 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Nutriband Inc. Warrant
Company Overview
History and Background
Nutriband Inc. is a pharmaceutical company focused on the development and commercialization of transdermal drug delivery systems. Their focus is abuse-deterrent transdermal technology. Information specific to the warrants history is limited. The warrants are derivative securities providing the right to purchase common stock under specific terms.
Core Business Areas
- Transdermal Drug Delivery: Development and commercialization of transdermal patches for various medications, primarily focused on abuse-deterrent formulations.
Leadership and Structure
Garrett D. Johnson is the CEO. The company operates with a standard corporate structure with departments focused on research and development, manufacturing, sales, and administration.
Top Products and Market Share
Key Offerings
- AvertRx: Abuse-deterrent transdermal naltrexone patch for opioid abuse prevention. Nutriband is awaiting FDA approval and currently has no market share or revenue. Competitors include injectable naltrexone (Vivitrol) and oral naltrexone.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. There is growing demand for abuse-deterrent formulations and novel drug delivery methods.
Positioning
Nutriband is a small company seeking to establish itself in the transdermal drug delivery market with a focus on abuse-deterrent technology. Competitive advantages, pending FDA approval, could be the transdermal delivery mechanism providing potentially improved patient compliance.
Total Addressable Market (TAM)
The TAM for opioid abuse treatment is estimated at several billion USD annually. Nutriband's positioning within this TAM is dependent on regulatory approvals and commercial success.
Upturn SWOT Analysis
Strengths
- Proprietary abuse-deterrent transdermal technology
- Focus on unmet medical needs
- Potential for improved patient compliance with transdermal delivery
Weaknesses
- Limited financial resources
- Dependence on regulatory approvals
- Small market capitalization
- High debt burden
Opportunities
- FDA approval of AvertRx
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increased government funding for opioid abuse prevention
Threats
- Competition from established pharmaceutical companies
- Delays in regulatory approvals
- Changes in healthcare policy
- Patent challenges
Competitors and Market Share
Key Competitors
- VTRS
- ALKS
- ITCI
Competitive Landscape
Nutriband faces significant competition from larger, more established pharmaceutical companies. Its success depends on its ability to secure regulatory approvals, establish strategic partnerships, and effectively market its products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company being in the development stage.
Future Projections: Future growth is dependent on FDA approval of AvertRx and subsequent commercialization. Analyst estimates, if available, are highly speculative.
Recent Initiatives: Recent initiatives include pursuing FDA approval for AvertRx and seeking strategic partnerships.
Summary
Nutriband Inc. Warrant is a high-risk, high-reward investment. The company's future hinges on the successful development and commercialization of its abuse-deterrent transdermal technology. While its proprietary technology and focus on unmet medical needs are strengths, its limited financial resources and dependence on regulatory approvals pose significant challenges. Investors should carefully consider these factors before investing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q), press releases, industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investing in micro-cap stocks involves significant risks, including the potential for complete loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nutriband Inc. Warrant
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2021-10-01 | Founder, CEO & Director Mr. Gareth Sheridan | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nutriband.com |
Full time employees - | Website https://www.nutriband.com | ||
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.